Guardant Health (GH) vs Labcorp (LH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Guardant Health (GH) has outperformed Labcorp (LH) over the past year, gaining 153.5% versus a gain of 13.2%. Over five years, GH leads with a +65.7% price change compared with +34.7% for LH. Labcorp is the larger company by market cap ($25.48 billion vs $22.22 billion), about 1.1 times the size, while Guardant Health is growing revenue faster (+32.9% vs +7.2%).
Labcorp pays a dividend yielding 0.92%, while Guardant Health does not currently pay one. Labcorp converts more of its revenue into profit, with a net margin of 6.3% versus -42.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GH | LH |
|---|---|---|
| Share price | $165.56 | $314.20 |
| Market cap | $22.22B | $25.48B |
| 1-day change | -1.65% | +0.71% |
| YTD return | +62.09% | +25.24% |
| 1-year return | +153.46% | +13.22% |
| 5-year return | +65.68% | +34.66% |
| P/E ratio (TTM) | — | 25.99 |
| Forward P/E | — | 15.86 |
| EPS (TTM) | $-3.50 | $12.09 |
| Dividend yield | 0.00% | 0.92% |
| Annual dividend | $0.00 | $2.88 |
| Revenue (latest FY) | $982.02M | $13.95B |
| Revenue growth (YoY) | +32.88% | +7.25% |
| Net income (latest FY) | $-416.28M | $876.50M |
| Gross margin | 64.46% | 28.76% |
| Operating margin | -44.53% | 9.92% |
| Net margin | -42.39% | 6.28% |
| 52-week high | $191.05 | $341.80 |
| 52-week low | $61.00 | $244.52 |
| Distance from 52-week high | -13.34% | -8.07% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +20.71% | +9.54% |
| Average volume | 1.98M | 742.58K |
| Shares outstanding | 134.20M | 81.10M |
| Employees | 2,490 | 71,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GH has outperformed LH by 140.2 percentage points over the past year.
- Labcorp is more profitable, keeping 6.3 cents of every revenue dollar as net income versus -42.4 cents for Guardant Health.
- Guardant Health grew revenue faster in its latest fiscal year (+32.88% vs +7.25%).
About Guardant Health
GH stock →Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.
Health Care · Medical Specialities · 2,490 employees
About Labcorp
LH stock →Labcorp Holdings Inc. provides laboratory services.
Health Care · Medical Specialities · 71,000 employees
GH vs LH FAQ
Which is bigger, Guardant Health or Labcorp?
Labcorp (LH) is larger, with a market capitalization of $25.48B compared with $22.22B for Guardant Health (GH).
Which stock has performed better over the past year, GH or LH?
GH returned +153.46% over the past 12 months, compared with +13.22% for LH (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Guardant Health or Labcorp?
Labcorp pays a dividend yielding 0.92%, while Guardant Health does not currently pay a regular dividend.
Are Guardant Health and Labcorp in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.